clevidipine trade name cleviprex dihydropyridine calcium channel blocker indicated reduction blood pressure oral therapy feasible desirable clevidipine used iv practitioners titrate drug lower blood pressure halflife approximately one minute rapidly inactivated esterases approved united states food drug administration august clevidipine dihydropyridine ltype calcium channel blocker highly selective vascular opposed myocardial smooth muscle therefore little effect myocardial contractility cardiac conduction reduces mean arterial blood pressure decreasing systemic vascular resistance clevidipine reduce cardiac filling pressure preload confirming lack effects venous capacitance vessels increase myocardial lactate production coronary sinus blood seen confirming absence myocardial ischemia due coronary steal clevidipine rapidly metabolized esterases blood extravascular tissues therefore elimination unlikely affected hepatic liver renal kidney dysfunction clevidipine accumulate body clearance independent body weight initial phase halflife approximately minute terminal halflife approximately minutes clevidipine still rapidly metabolized pseudocholinesterasedeficient patients clevidipine formulated lipid emulsion soybean oil intralipid contains approximately g fat per ml kcalml clevidipine also contains glycerin mgml purified egg yolk phospholipids mgml sodium hydroxide adjust ph clevidipine ph perioperative patient population clevidipine produces reduction systolic blood pressure within minutes starting mghour iv infusion studies hours continuous infusion evidence tolerance patients full recovery blood pressure achieved minutes infusion stopped clevidipine contains stereocenter consists two enantiomers racemate ie mixture r aseptic technique used handling cleviprex since contains phospholipids support microbial growth cleviprex administered intravenously titrated achieve desired blood pressure reduction blood pressure heart rate monitored continually infusion cleviprex single use product diluted administered line medications stopper punctured cleviprex used within hours unused portion remaining vial discarded change iv lines accordance hospital protocol iv infusion mghour recommended initiation titrated doubling dose every seconds blood pressure approaches goal infusion rate increased smaller increments titrated less frequently maximum infusion rate cleviprex mghour patients clinical trials treated doses mghour less lipid load restrictions ml average mghour cleviprex infusion recommended per hours clinical studies significant changes occurred serum triglyceride levels cleviprex treated patients little experience infusion durations beyond hours dose infusion reduced discontinued achieve desired blood pressure appropriate oral therapy established cleviprex intended intravenous use titrate drug depending response individual patient achieve desired blood pressure reduction monitor blood pressure heart rate continually infusion vital signs stable patients receive prolonged cleviprex infusions transitioned antihypertensive therapies monitored possibility rebound hypertension least hours infusion stopped clinical trials safety profile clevidipine generally similar sodium nitroprusside nitroglycerin nicardipine patients undergoing cardiac cleviprex contraindicated patients allergies soybeans soy products eggs egg products defective lipid metabolism pathologic hyperlipemia rare genetic disorders characterized abnormal triglyceride metabolism lipoid nephrosis acute pancreatitis accompanied hyperlipidemia patients severe aortic stenosis hypotension reflex tachycardia potential consequences rapid upward titration cleviprex clinical trials similar increase heart rate observed cleviprex comparator arms dihydropyridine calcium channel blockers produce negative inotropic effects exacerbate heart failure heart failure patients monitored carefully cleviprex gives protection effects abrupt betablocker withdrawal common adverse reactions headache nausea vomiting cleviprex used pregnancy potential benefit justifies potential risk fetus maintain aseptic technique handling cleviprex cleviprex contains phospholipids support microbial growth use contamination suspected stopper punctured use discard within hours clinical drug interaction studies conducted cleviprex potential blocking inducing cyp enzymes cleviprex available readytouse glass vials concentration mgml clevidipine butyrate vials refrigerated cleviprex stored controlled room temperature months cleviprex photosensitive storage cartons protects photodegradation protection light administration required cleviprex evaluated phase iii clinical studies including perioperative emergency departmentintensive care settings include eclipse velocity trials doubleblind randomized placebocontrolled efficacy trial cardiac surgery patients cleviprex significantly lower rate treatment failure compared placebo vs rate success lowering systolic blood pressure sbp median time reduce sbp baseline minutes doubleblind randomized placebocontrolled efficacy trials cardiac surgery patients cleviprex significantly lower rate treatment failure compared placebo vs treatment success rate median time reduce sbp baseline minutes eclipse trials consisted three safety trials patients randomized receive cleviprex nitroglycerin sodium nitroprusside nicardipine treatment hypertension associated cardiac surgery incidence death stroke myocardial infarction heart attack renal dysfunction days differ significantly pooled cleviprex comparator treatment arms velocity openlabel trial patients severe hypertension bp mmhg emergency department intensive care unit velocity patients achieved target sbp mean decrease minutes httpsenwikipediaorgwikiclevidipine